Samvel B. Gasparyan

Samvel B. Gasparyan

Auto-generated profile, based on publicly available information

Samvel B. Gasparyan

Late Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Boston, MA (S.B.G.).

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
PJPardeep S. Jhund
Pardeep S. Jhund
TKToru Kondo
Toru Kondo
JBJawad H. Butt
Jawad H. Butt
KDKieran F. Docherty
Kieran F. Docherty
BCBrian L. Claggett
Brian L. Claggett
JMJohn J. V. McMurray
John J. V. McMurray
Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction (≤40% and >40%) was pre-specified to examine the effect of treatment on endpoints that neither trial, individually, was powered for and to test the consistency of the effect of dapagliflozin across the range of ejection fractions. The pre-specified endpoints were: death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction or stroke (major adverse cardiovascular events (MACEs)). A total of 11,007 participants with a mean ejection fraction of 44% (s.d. 14%) were included. Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76–0.97; P = 0.01), death from any cause (HR 0.90, 95% CI 0.82–0.99; P = 0.03), total hospital admissions for heart failure (rate ratio 0.71, 95% CI 0.65–0.78; P < 0.001) and MACEs (HR 0.90, 95% CI 0.81–1.00; P = 0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction. In a patient-level pooled meta-analysis covering the full range of ejection fractions in patients with heart failure, dapagliflozin reduced the risk of death from cardiovascular causes and hospital admissions for heart failure (PROSPERO: CRD42022346524).

1 September 2021 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
MKMikhail N Kosiborod
Mikhail N Kosiborod
RERussell Esterline
Russell Esterline
RFRemo H M Furtado
Remo H M Furtado
JOJan Oscarsson
Jan Oscarsson
SGSamvel B Gasparyan
Samvel B Gasparyan
OBOtavio Berwanger
Otavio Berwanger

18 May 2021 in Circulation
Verified
Journal Article
Open access
PDF file
PJPardeep S. Jhund
Pardeep S. Jhund
PPPiotr Ponikowski
Piotr Ponikowski
KDKieran F. Docherty
Kieran F. Docherty
SGSamvel B. Gasparyan
Samvel B. Gasparyan
MBMicheal Böhm
Micheal Böhm
JMJohn J.V. McMurray
John J.V. McMurray
Background: Patients with heart failure (HF) and reduced ejection fraction will experience multiple hospitalizations for heart failure during the course of their disease. We assessed the efficacy of dapagliflozin on reducing the rate of total (ie, first and repeat) hospitalizations for heart failure in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure). Methods: The total number of HF hospitalizations and cardiovascular deaths was examined by using the proportional-rates approach of Lei-Wei-Yang-Ying and a joint frailty model for each of recurrent HF hospitalizations and time to cardiovascular death. Variables associated with the risk of recurrent hospitalizations were explored in a multivariable Lei-Wei-Yang-Ying model. Results: Of 2371 participants randomly assigned to placebo, 318 experienced 469 hospitalizations for HF; of 2373 assigned to dapagliflozin, 230 patients experienced 340 admissions. In a multivariable model, factors associated with a higher risk of recurrent HF hospitalizations included higher heart rate, higher N-terminal pro-B-type natriuretic peptide, and New York Heart Association class. In the Lei-Wei-Yang-Ying model, the rate ratio for the effect of dapagliflozin on recurrent HF hospitalizations or cardiovascular death was 0.75 (95% CI, 0.65–0.88), P =0.0002. In the joint frailty model, the rate ratio for total HF hospitalizations was 0.71 (95% CI, 0.61–0.82), P <0.0001, whereas, for cardiovascular death, the hazard ratio was 0.81 (95% CI, 0.67–0.98), P =0.0282. Conclusions: Dapagliflozin reduced the risk of total (first and repeat) HF hospitalizations and cardiovascular death. Time-to-first event analysis underestimated the benefit of dapagliflozin in HF and reduced ejection fraction. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03036124.

29 July 2020 in Statistical Methods in Medical Research
Verified
Journal Article
Closed access
PDF file
SGSamvel B Gasparyan
Samvel B Gasparyan
FFFolke Folkvaljon
Folke Folkvaljon
OBOlof Bengtsson
Olof Bengtsson
JBJoan Buenconsejo
Joan Buenconsejo
GKGary G Koch
Gary G Koch
The win ratio is a general method of comparing locations of distributions of two independent, ordinal random variables, and it can be estimated without distributional assumptions. In this paper we provide a unified theory of win ratio estimation in the presence of stratification and adjustment by a numeric variable. Building step by step on the estimate of the crude win ratio we compare corresponding tests with well known non-parametric tests of group difference (Wilcoxon rank-sum test, Fligner–Policello test, van Elteren test, test based on the regression on ranks, and the rank analysis of covariance test). We show that the win ratio gives an interpretable treatment effect measure with corresponding test to detect treatment effect difference under minimal assumptions.

24 October 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
HHHiddo Heerspink
Hiddo Heerspink
NJNiels Jongs
Niels Jongs
PSPatrick Schloemer
Patrick Schloemer
DLDustin J. Little
Dustin J. Little
MBMeike Brinker
Meike Brinker
SGSamvel B. Gasparyan
Samvel B. Gasparyan
Significance Statement: The established composite kidney end point in clinical trials combines clinical events with sustained large changes in GFR but does not weigh the relative clinical importance of the end point components. By contrast, a hierarchical composite end point (HCE) accounts for the clinical importance of the end point components. The authors developed and validated a kidney HCE that combines clinical kidney outcomes with longitudinal GFR changes (GFR slope). They demonstrate that in seven major placebo-controlled kidney outcome trials with different medications, treatment effect estimates on the HCE were consistently in similar directions and of similar magnitudes compared with treatment effects on the established kidney end point. The HCE's prioritization of clinical outcomes and ability to combine dichotomous outcomes with GFR slope make it an attractive alternative to the established kidney end point. Background: The established composite kidney end point in clinical trials combines clinical events with sustained large changes in GFR. However, the statistical method does not weigh the relative clinical importance of the end point components. A HCE accounts for the clinical importance of the end point components and enables combining dichotomous outcomes with continuous measures. Methods: We developed and validated a new HCE for kidney disease progression, performing post hoc analyses of seven major Phase 3 placebo-controlled trials that assessed the effects of canagliflozin, dapagliflozin, finerenone, atrasentan, losartan, irbesartan, and aliskiren in patients with CKD. We calculated the win odds (WOs) for treatment effects on a kidney HCE, defined as a hierarchical composite of all-cause mortality; kidney failure; sustained 57%, 50%, and 40% GFR declines from baseline; and GFR slope. The WO describes the odds of a more favorable outcome for receiving the active compared with the control. We compared the WO with the hazard ratio (HR) of the primary kidney outcome of the original trials. Results: In all trials, treatment effects calculated with the WO reflected a similar direction and magnitude of the treatment effect compared with the HR. Clinical trials incorporating the HCE would achieve increased statistical power compared with the established composite end point at equivalent sample sizes. Conclusions: In seven major kidney clinical trials, the WO and HR provided similar direction of treatment effect estimates with smaller HRs associated with larger WOs. The prioritization of clinical outcomes and inclusion of broader composite end points makes the HCE an attractive alternative to the established kidney end point.

15 December 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
MKMikhail Kosiborod
Mikhail Kosiborod
OBOtavio Berwanger
Otavio Berwanger
GKGary G. Koch
Gary G. Koch
FMFelipe Martinez
Felipe Martinez
OMOmar Mukhtar
Omar Mukhtar
RERussell Esterline
Russell Esterline
Aims Coronavirus disease 2019 (COVID‐19) is caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant associated morbidity and mortality, particularly in patients with underlying metabolic, cardiovascular, respiratory, or kidney disease. Dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, has shown significant cardio‐ and renoprotective benefits in patients with type 2 diabetes (with and without atherosclerotic cardiovascular disease), heart failure, and chronic kidney disease, and may provide similar organ protection in high‐risk patients with COVID‐19. Materials and methods DARE‐19 (NCT04350593) is an investigator‐initiated, collaborative, international, multicenter, randomized, double‐blind, placebo‐controlled study testing the dual hypotheses that dapagliflozin can reduce the incidence of cardiovascular, kidney and/or respiratory complications or all‐cause mortality, or improve clinical recovery, in adult patients hospitalized with COVID‐19 but not critically ill on admission. Eligible patients will have ≥1 cardiometabolic risk factor for COVID‐19 complications. Patients will be randomized 1:1 to dapagliflozin 10 mg or placebo. Primary efficacy endpoints are time to development of new or worsened organ dysfunction during index hospitalization, or all‐cause mortality, and the hierarchical composite endpoint of change in clinical status through Day 30 of treatment. Safety of dapagliflozin in individuals with COVID‐19 will be assessed. Conclusions DARE‐19 will evaluate whether dapagliflozin can prevent COVID‐19‐related complications and all‐cause mortality, or improve clinical recovery, and assess dapagliflozin's safety profile in this patient population. Currently, DARE‐19 is the first large randomized controlled trial investigating use of SGLT2 inhibitors in patients with COVID‐19.